Cargando…

Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications

Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhiyang, Peng, Bi, Li, Juanni, Gao, Kewa, Cai, Yuan, Xu, Zhijie, Yan, Yuanliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443600/
https://www.ncbi.nlm.nih.gov/pubmed/34526571
http://dx.doi.org/10.1038/s41598-021-97840-0
_version_ 1783753216185335808
author Zhou, Zhiyang
Peng, Bi
Li, Juanni
Gao, Kewa
Cai, Yuan
Xu, Zhijie
Yan, Yuanliang
author_facet Zhou, Zhiyang
Peng, Bi
Li, Juanni
Gao, Kewa
Cai, Yuan
Xu, Zhijie
Yan, Yuanliang
author_sort Zhou, Zhiyang
collection PubMed
description Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively analyzed the MEK1 alteration spectrum and provided novel insight for targeted therapies. There were 7694 samples covering 32 types of cancer from The Cancer Genome Atlas (TCGA) database. They were used to conduct an integrative analysis of MEK1 expression, alterations, functional impacts and clinical significance. There was a dramatic difference in the alteration frequency and distribution and clinical implications in 32 types of cancer from the TCGA. Skin cutaneous melanoma (SKCM) has the most alterations and has therapeutic targets located in the protein kinase domain, and the growing expression of SKCM is positively related to patient prognosis. MEK1 expression in lung adenocarcinoma (LUAD), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA) and liver hepatocellular carcinoma (LIHC) is decreased, which is associated with better prognosis, while MEK1 expression in thymoma (THYM), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), testicular germ cell tumors (TGCTs) and head and neck squamous cell carcinoma (HNSC) is increased, which is associated with better prognosis. Mesothelioma (MESO) has the second highest alterations but has no therapy targets. This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective.
format Online
Article
Text
id pubmed-8443600
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84436002021-09-20 Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications Zhou, Zhiyang Peng, Bi Li, Juanni Gao, Kewa Cai, Yuan Xu, Zhijie Yan, Yuanliang Sci Rep Article Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively analyzed the MEK1 alteration spectrum and provided novel insight for targeted therapies. There were 7694 samples covering 32 types of cancer from The Cancer Genome Atlas (TCGA) database. They were used to conduct an integrative analysis of MEK1 expression, alterations, functional impacts and clinical significance. There was a dramatic difference in the alteration frequency and distribution and clinical implications in 32 types of cancer from the TCGA. Skin cutaneous melanoma (SKCM) has the most alterations and has therapeutic targets located in the protein kinase domain, and the growing expression of SKCM is positively related to patient prognosis. MEK1 expression in lung adenocarcinoma (LUAD), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA) and liver hepatocellular carcinoma (LIHC) is decreased, which is associated with better prognosis, while MEK1 expression in thymoma (THYM), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), testicular germ cell tumors (TGCTs) and head and neck squamous cell carcinoma (HNSC) is increased, which is associated with better prognosis. Mesothelioma (MESO) has the second highest alterations but has no therapy targets. This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective. Nature Publishing Group UK 2021-09-15 /pmc/articles/PMC8443600/ /pubmed/34526571 http://dx.doi.org/10.1038/s41598-021-97840-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhou, Zhiyang
Peng, Bi
Li, Juanni
Gao, Kewa
Cai, Yuan
Xu, Zhijie
Yan, Yuanliang
Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_full Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_fullStr Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_full_unstemmed Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_short Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_sort integrative pan-cancer analysis of mek1 aberrations and the potential clinical implications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443600/
https://www.ncbi.nlm.nih.gov/pubmed/34526571
http://dx.doi.org/10.1038/s41598-021-97840-0
work_keys_str_mv AT zhouzhiyang integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
AT pengbi integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
AT lijuanni integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
AT gaokewa integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
AT caiyuan integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
AT xuzhijie integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
AT yanyuanliang integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications